Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine Relapse Prevention in Pediatric Depression
NCT05014919Phase 3Terminated
- Sponsor
- Lundbeck
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Aug 2021; status: terminated.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05014919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05014919.